Drugs that contain Peginesatide Acetate
1. Drug name - OMONTYS
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7084245 | TAKEDA PHARMS USA | Peptides that bind to the erythropoietin receptor |
May, 2024
(1 year, 7 months from now) | |
| US7414105 | TAKEDA PHARMS USA | Peptides that bind to the erythropoietin receptor |
May, 2024
(1 year, 7 months from now) | |
| US7919118 | TAKEDA PHARMS USA | Spacer moiety for poly (ethylene glycol) modified peptide based compounds |
May, 2024
(1 year, 7 months from now) | |
| US7528104 | TAKEDA PHARMS USA | Peptides that bind to the erythropoietin receptor |
May, 2024
(1 year, 7 months from now) | |
| CN1823088B | TAKEDA PHARMS USA | Novel Peptides That Bind To The Erythropoietin Receptor |
Jul, 2015
(7 years ago) | |
| CN1823088A | TAKEDA PHARMS USA | Generating New Peptide Receptor Binding |
Jul, 2015
(7 years ago) | |
| CN1823087A | TAKEDA PHARMS USA | Generating New Peptide Receptor Binding |
Apr, 2019
(3 years ago) | |
| CN100441595C | TAKEDA PHARMS USA | Novel Peptides That Bind To The Erythropoietin Receptor |
Apr, 2019
(3 years ago) | |
| IN200502499P2 | TAKEDA PHARMS USA | A Peptide Dimer |
May, 2024
(1 year, 7 months from now) | |
| IN224732B | TAKEDA PHARMS USA | A Peptide Dimer |
May, 2024
(1 year, 7 months from now) | |
| IN200502493P2 | TAKEDA PHARMS USA | A Peptide Cross-Reference To Related Applications |
May, 2024
(1 year, 7 months from now) | |
| IN228387B | TAKEDA PHARMS USA | A Peptide |
May, 2024
(1 year, 7 months from now) | |
| EP1629007B1 | TAKEDA PHARMS USA | Novel Peptides That Bind To The Erythropoietin Receptor |
May, 2024
(1 year, 7 months from now) | |
| EP1625156B1 | TAKEDA PHARMS USA | Peptides That Bind To The Erythropoietin Receptor |
May, 2024
(1 year, 7 months from now) | |
| EP1629007A2 | TAKEDA PHARMS USA | Novel Peptides That Bind To The Erythropoietin Receptor |
May, 2024
(1 year, 7 months from now) | |
| EP1625156A2 | TAKEDA PHARMS USA | Peptides That Bind To The Erythropoietin Receptor |
May, 2024
(1 year, 7 months from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7550433 | TAKEDA PHARMS USA | Erythropoietin receptor peptide formulations and uses |
Jun, 2026
(3 years from now) | |
| US7919461 | TAKEDA PHARMS USA | Erythropoietin receptor peptide formulations and uses |
Jun, 2026
(3 years from now) | |
Treatment: Treatment of anemia due to chronic kidney disease
Dosage: SOLUTION;INTRAVENOUS, SUBCUTANEOUS
More Information on Dosage
| Strength | Dosage | Availability |
|---|---|---|
| EQ 10MG BASE/ML (EQ 10MG BASE/ML) | SOLUTION;INTRAVENOUS, SUBCUTANEOUS | Discontinued |
| EQ 20MG BASE/2ML (EQ 10MG BASE/ML) | SOLUTION;INTRAVENOUS, SUBCUTANEOUS | Discontinued |
| EQ 1MG BASE/0.5ML (EQ 1MG BASE/0.5ML) | SOLUTION;INTRAVENOUS, SUBCUTANEOUS | Discontinued |
| EQ 2MG BASE/0.5ML (EQ 2MG BASE/0.5ML) | SOLUTION;INTRAVENOUS, SUBCUTANEOUS | Discontinued |
| EQ 3MG BASE/0.5ML (EQ 3MG BASE/0.5ML) | SOLUTION;INTRAVENOUS, SUBCUTANEOUS | Discontinued |
| EQ 4MG BASE/0.5ML (EQ 4MG BASE/0.5ML) | SOLUTION;INTRAVENOUS, SUBCUTANEOUS | Discontinued |
| EQ 5MG BASE/0.5ML (EQ 5MG BASE/0.5ML) | SOLUTION;INTRAVENOUS, SUBCUTANEOUS | Discontinued |
| EQ 6MG BASE/0.5ML (EQ 6MG BASE/0.5ML) | SOLUTION;INTRAVENOUS, SUBCUTANEOUS | Discontinued |
availability in other generic markets.
Click on the highlighted region to filter.